Fig. 1.

Protective effect of WT1-pTj in vivo. (A) Lung colonization of B16F10-Nex2 endovenously inoculated in C57BL/6 mice. Animals received 5 i.p. doses of 300 μg of C PEP, 300 μg of WT1-pTj or vehicle (PBS) on consecutive days; ^*p = 0.02 versus C PEP. (B) Effect of WT1-pTj on subcutaneous growth of B16F10-nex2 melanoma tumor. Once nodules reached 200 mm³, mice were randomized and received 5 alternate i.p. injections of 300 μg of WT1-pTj or C PEP; ^*p < 0.05 versus C PEP. (C) Effect of WT1-pTj on A2058 tumor growth in nude mice. Animals were treated with peritumor injections of 300 μg of WT1-pTj, 300 μg of C PEP or vehicle (PBS) for 5 consecutive days, starting on day 1 post-tumor cell challenge; ^*p < 0.05 in comparison with C PEP. (D) Survival of nude mice grafted with human melanoma after treatment with WT1-pTj, C PEP or PBS; n = 5 mice per group; ^*p = 0.0185 in comparison with C PEP.